Roche's anti-TIGIT drug suffers a phase III cancer setback

被引：6
作者：
Mullard, Asher
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2022年 / 21卷 / 05期
关键词：
D O I：
10.1038/d41573-022-00068-4
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：327 / 327
页数：1
相关论文
共 50 条
  • [21] A phase Ia trial to evaluate the safety and efficacy of HB0030, an anti-TIGIT antibody, in patients with advanced solid tumors: Preliminary results
    Zhou, Huan
    Li, Wei
    Xie, Jing
    Li, Hongtao
    Zhu, Xiangyang
    Yang, Yongmin
    Yang, Yang
    Zheng, Yang
    Wang, Qiaofeng
    Chen, Juan
    Li, Chao
    Xu, Ruirui
    Wang, Jingjing
    He, Yiran
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [22] AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors
    Frentzas, Sophia
    Kao, Steven
    Gao, Rang
    Zheng, Hao
    Rizwan, Ahsan
    Budha, Nageshwar
    Pedroza, Luz de la Hoz
    Tan, Wei
    Meniawy, Tarek
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
  • [23] PHASE 3 STUDY OF FIRST-LINE PEMBROLIZUMAB WITH AND WITHOUT VIBOSTOLIMAB (ANTI-TIGIT) IN PATIENTS WITH PD-L1-POSITIVE METASTATIC NSCLC
    Hellmann, Matthew
    Cho, Byoung
    Juergens, Rosalyn
    Cheng, Ying
    de Castro, Gilberto
    Erman, Mustafa
    Bauman, Jessica
    Takahashi, Toshiaki
    Schwarzenberger, Paul
    Zhang, Pingye
    Pietanza, M. Catherine
    Yang, James Chih-Hsin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A488 - A488
  • [24] Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors
    Bendell, Johanna C.
    Bedard, Philippe
    Bang, Yung-Jue
    LoRusso, Patricia
    Hodi, Stephen
    Gordon, Michael
    D'Angelo, Sandra
    Desai, Jayesh
    Garralda, Elena
    Italiano, Antoine
    Myung-Ju Ahn
    Cervantes, Andres
    Wainberg, Zev
    Calvo, Emiliano
    Gil-Martin, Marta
    Martinez-Garcia, Maria
    Bahleda, Rastilav
    Cassier, Philippe
    Delord, Jean-Pierre
    Prawira, Amy
    Melero, Ignacio
    Emens, Leisha
    Romano, Emanuela
    Miller, Karen
    Hsieh, Robert W.
    Xue, Cloris
    Morrissey, Kari
    Twomey, Patrick
    Gash, Kelly
    Patil, Namrata S.
    Grogan, Jane
    Meng, Raymond
    Cho, Byoung
    Kim, Tae Won
    CANCER RESEARCH, 2020, 80 (16)
  • [25] Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors (jan, 10.1007/s00280-023-04627-3, 2024)
    Yamamoto, Noboru
    Koyama, Takafumi
    Sato, Jun
    Yoshida, Tatsuya
    Sudo, Kazuki
    Iwasa, Satoru
    Kondo, Shunsuke
    Yonemori, Kan
    Kawasaki, Atsuko
    Satake, Kyoko
    Shibata, Shoyo
    Shimizu, Toshio
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2024, 94 (03) : 491 - 491
  • [26] Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors A Phase 1a/1b Nonrandomized Controlled Trial
    Kim, Tae Won
    Bedard, Philippe L.
    Lorusso, Patricia
    Gordon, Michael S.
    Bendell, Johanna
    Oh, Do-Youn
    Ahn, Myung-Ju
    Garralda, Elena
    D'Angelo, Sandra P.
    Desai, Jayesh
    Hodi, F. Stephen
    Wainberg, Zev
    Delord, Jean-Pierre
    Cassier, Phillippe A.
    Cervantes, Andres
    Gil-Martin, Marta
    Wu, Benjamin
    Patil, Namrata S.
    Jin, Yanling
    Hoang, Tien
    Mendus, Diana
    Wen, Xiaohui
    Meng, Raymond
    Cho, Byoung Chul
    JAMA ONCOLOGY, 2023, 9 (11) : 1574 - 1582
  • [27] AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.
    Wu, Lingying
    Wang, Peng-Hui
    Hsiao, Sheng-Yen
    Chang, Chih-Long
    Kim, Hee Seung
    Lee, Jung-Yun
    Ryu, Sang-Young
    Zuo, Yunxia
    Mu, Xiyan
    Gao, Yujuan
    Yang, Silu
    Lee, Jae-Kwan
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] Anti-TIGIT upregulate CD226 on CD8+T cell as a potential therapeutic manner in HER2 positive breast cancer
    Zhang, Liyi
    Zhang, Qi
    Wang, Zehao
    Shao, Zhibo
    Xue, Jingyan
    Chi, Yayun
    Xiu, Bingqiu
    Wu, Jiong
    CANCER RESEARCH, 2024, 84 (09)
  • [29] Integration of Anti-TIGIT and anti-Lag3 with NBTXR3-mediated Immunoradiation Therapy Improves Abscopal Effect and Induces Long-term Memory Against Cancer
    Hu, Yun
    Schuda, Lily
    Paris, Sebastien
    Barsoumian, Hampartsoum
    Cortez, Angelica
    Welsh, James
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2021, 44 (10): : S110 - S110
  • [30] Phase 1 trials of Meditech's HyACT™ anti-cancer drug
    不详
    AUSTRALASIAN BIOTECHNOLOGY, 2002, 12 (04) : 18 - 18
12345